Translocations or amplifications on top of the genomic alterations currently current in the initial CLL, but lack the prevalent mutations observed in Major DLBCL indicating that they might correspond to a distinct biological classification. This feature could be especially valuable for non-compliant patients or Individuals in whom ibrutinib is contraindicated. https://peterm430ktb9.azuria-wiki.com/user